No cameras are permitted. No transcripts are available. Only shareholders may attend. But we have a ringside seat at the Berkshire Hathaway annual meeting. Here's what Warren Buffett, the Oracle of Omaha said in this year's Q&A.
This weekend, more than 40,000 of Warren Buffett's disciples will descend on his hometown for Berkshire Hathaway's annual shareholder meeting, where, among other things, they'll take part in a marathon Q&A session with the Oracle of Omaha himself. Here are three subjects sure to come up.
Mild panic swept through Berkshire Hathaway's shareholders Tuesday after Warren Buffet announced he had prostate cancer. But the panic was brief, and not just because the disease isn't life threatening.
Warren Buffett, the legendary investor and head of Berkshire Hathaway, announced Tuesday that he has stage 1 prostate cancer, which he describes as "not remotely life threatening or even debilitating in any meaningful way."
Dendreon's Provenge, which targets prostate cancer, catapulted that company's stock to record highs recently. Prima Biomed's CVac works similarly, but it has the potential to target multiple forms of cancer, giving the company an intriguing future.
The stock sank on Thursday after the Centers for Medicare and Medicaid Services said it was evaluating data on Provenge, the company's prostate cancer vaccine, to decide whether to cover the drug for seniors nationwide.
Prostate cancer patients face rationing and delays of Dendreon's breakthrough treatment Provenge. The drug maker says it can only produce enough of the vaccine to treat about 2% of eligible patients until manufacturing increases in mid-2011.
If you could prevent cancer by taking a pill, would you? Probably. Should you? That's a matter of debate among doctors. Merck's Proscar and now GlaxoSmithKline's Avodart have been shown in studies to cut prostate cancers. But whether those studies are conclusive is the question.
